wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38630725-272F9279-EFF5-475A-A5B3-D1B2F0915A07
Q38630725-272F9279-EFF5-475A-A5B3-D1B2F0915A07
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38630725-272F9279-EFF5-475A-A5B3-D1B2F0915A07
Safety and efficacy of targeted agents monotherapy in advanced NSCLC.
P2860
Q38630725-272F9279-EFF5-475A-A5B3-D1B2F0915A07
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38630725-272F9279-EFF5-475A-A5B3-D1B2F0915A07
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8a5a1d83546a9d2c420f62b683ec94f3cffc15e2
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.